ER-100 targets glaucoma and NAION through epigenetic reprogramming, with Phase II trials advancing, highlighting potential economic and healthcare disruptions in anti-aging therapies. Life Biosciences...
ARPA-H’s PROSPR program directs over $50 million to aging trials, advancing drugs like Cambrian’s rapamycin analog and Linnaeus’s GPER-targeter, signaling a shift in treating aging a...
Recent studies validate blood biomarkers like p-tau217 for predicting Alzheimer’s onset within 3-4 years at 94% accuracy, enabling early interventions but raising ethical and socioeconomic conce...
In 2025, aging research sees major advancements with senolytics and mitochondrial therapies, backed by clinical trials and shifting medical attitudes towards treating aging as a condition. Recent tria...
Artificial intelligence enhances breast cancer screening through improved mammography accuracy and explainable models, reducing false positives and mortality rates, as shown in recent research. Recent...
